Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467590 | PMC |
| http://dx.doi.org/10.1590/S1806-37562017000000325 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Gut microbial alteration in chronic spontaneous urticaria unresponsive to second generation antihistamines and its correlation with disease characteristics- a cross-sectional case-control study.
Clin Transl Allergy
January 2025
Department of Dermatology, Hospital del Mar Research Institute, Barcelona, Spain.
Background: Gut microbial involvement has been speculated in chronic spontaneous urticaria (CSU). The aim of the study was to compare the gut microbiome composition and diversity in CSU patients uncontrolled with second-generation antihistamines (sgAHs) and healthy individuals, as well as to explore any association between gut microbiome and disease characteristics.
Methods: A cross-sectional case-control study including 20 CSU patients unresponsive to standard doses of sgAHs, and 15 age-and-sex matched healthy controls was conducted.
Factors influencing the prescription of add-on long-acting muscarinic antagonists in real-world asthma management: Insights from a national registry.
Respir Med
January 2025
Ankara University School of Medicine, Department of Chest Disease, Division of Immunology and Allergy, Ankara, Turkey.
Current guidelines recommend adding long-acting muscarinic antagonists (LAMAs) in patients with uncontrolled asthma, despite the use of moderate to high doses of inhaled steroid-long-acting beta agonists (ICS/LABA). This study aims to analyze the factors related to the prescription of add-on LAMA in clinical practice for asthma patients, shedding light on physicians' preferences. This study included adult asthma patients on add-on LAMA and ICS/LABA monitored for at least one year in a national registry comprising 2053 asthmatics.
View Article and Find Full Text PDFUpdated review of omalizumab to treat uncontrolled pediatric allergic asthma.
J Allergy Clin Immunol
January 2025
Los Altos, Calif.
Asthma has been increasingly recognized as a heterogeneous disease; however, many patients with asthma have allergic asthma (AA). Inhaled corticosteroids and other inhalers have been integral in treating many symptoms of asthma, but these medications do not completely address the disease's underlying mechanism. Pediatric asthma imposes a substantial burden on patients and the health care system.
View Article and Find Full Text PDFProtective Effect of Allergen Immunotherapy in Patients With Allergic Rhinitis and Asthma Against COVID-19 Infection: Observational, Nationwide, and Multicenter Study.
JMIR Public Health Surveill
October 2024
Department of Allergy and Clinical Immunology, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China, 86 189 2886 8259, 86 20 3429 8996.
Article Synopsis
- A study was conducted to explore how allergen immunotherapy (AIT) might protect against viral infections, particularly during a surge of COVID-19 cases among patients with allergic rhinitis (AR) and allergic asthma (AS) in China.
- The analysis included over 3,600 individuals who tested positive for COVID-19, comparing outcomes between patients receiving routine treatments versus those receiving AIT.
- Results indicated that patients receiving AIT experienced milder symptoms, quicker recoveries, and reduced rates of hospitalization compared to those only on routine medications, suggesting AIT may enhance protection against severe viral infections.
Treating severe paediatric asthma with mepolizumab or omalizumab: a protocol for the TREAT randomised non-inferiority trial.
BMJ Open
August 2024
National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, UK
Introduction: A minority of school-aged children with asthma have persistent poor control and experience frequent asthma attacks despite maximal prescribed maintenance therapy. These children have higher morbidity and risk of death. The first add-on biologic therapy, omalizumab, a monoclonal antibody that blocks immunoglobulin (Ig)E, was licensed for children with severe asthma in 2005.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!